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ABSTRACT:
Histone variants seem to play a major role in gene expression regulation. 
In prostate cancer, H2A.Z and its acetylated form are implicated in oncogenes’ 
upregulation. SIRT1, which may act either as tumor suppressor or oncogene, reduces 
H2A.Z levels in cardiomyocytes, via proteasome-mediated degradation, and this 
mechanism might be impaired in prostate cancer cells due to sirtuin 1 downregulation. 
Thus, we aimed to characterize the mechanisms underlying H2A.Z and SIRT1 
deregulation in prostate carcinogenesis and how they interact.
We found that H2AFZ and SIRT1 were up- and downregulated, respectively, at 
transcript level in primary prostate cancer and high-grade prostatic intraepithelial 
neoplasia compared to normal prostatic tissues. Induced SIRT1 overexpression in 
prostate cancer cell lines resulted in almost complete absence of H2A.Z. Inhibition 
of mTOR had a modest effect on H2A.Z levels, but proteasome inhibition prevented 
the marked reduction of H2A.Z due to sirtuin 1 overexpression. Prostate cancer cells 
exposed to epigenetic modifying drugs trichostatin A, alone or combined with 5-aza-
2’-deoxycytidine, increased H2AFZ transcript, although with a concomitant decrease 
in protein levels. Conversely, SIRT1 transcript and protein levels increased after 
exposure. ChIP revealed an increase of activation marks within the TSS region for 
both genes. Remarkably, inhibition of sirtuin 1 with nicotinamide, increased H2A.Z 
levels, whereas activation of sirtuin 1 by resveratrol led to an abrupt decrease in 
H2A.Z. Finally, protein-ligation assay showed that exposure to epigenetic modifying 
drugs fostered the interaction between sirtuin 1 and H2A.Z.
We concluded that sirtuin 1 and H2A.Z deregulation in prostate cancer are 
reciprocally related. Epigenetic mechanisms, mostly histone post-translational 
modifications, are likely involved and impair sirtuin 1-mediated downregulation 
of H2A.Z via proteasome-mediated degradation. Epigenetic modifying drugs in 
conjunction with enzymatic modulators are able to restore the normal functions of 
sirtuin 1 and might constitute relevant tools for targeted therapy of prostate cancer 
patients. 
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INTRODUCTION
Prostate cancer (PCa) is the second most common 
malignancy diagnosed in men worldwide, being one of the 
major causes of cancer-related morbidity and mortality[1]. 
Although mostly symptomatic only in advanced stages, 
PCa is characterized by early disruption of both genetic[2] 
and epigenetic[3] mechanisms, progressively becoming 
more severe throughout disease progression.
Alterations in histone variants are the least 
understood among epigenetic mechanisms deregulated 
in cancer. Histone variant H2A.Z, encoded by H2AFZ, 
whose insertion into chromatin is tightly regulated by 
complexes such as SRCAP, p400/Tip60 and TIP48/49 [4], 
plays a major role in critical biological processes, such 
as chromosome segregation [5], cell cycle progression [6] 
and maintenance of heterochromatin/euchromatin status 
[7]. Nevertheless, H2A.Z has been consistently associated 
with neoplastic transformation: H2AFZ overexpression 
has been reported in sporadic microsatellite unstable 
colorectal carcinoma [8], breast carcinoma [9, 10] and 
several undifferentiated cancers [11]. At a molecular level, 
this histone variant is responsible for overexpression of 
several proto-oncogenes, including C-MYC [9, 12].  In 
PCa, however, the role of H2A.Z remains elusive [13]. 
Increased expression of H2AFZ was found in a castration-
resistant xenograph model of PCa, suggesting that high 
levels of H2A.Z might be predictive to progression for 
androgen-independent disease [14]. Conversely, it has 
been claimed that acetylated H2A.Z (acH2A.Z), and not 
H2A.Z itself, was enriched (oncogenes) or lost (tumor 
suppressor genes, TSG) at the transcription start-site 
(TSS) of nucleosomes during carcinogenesis, suggesting 
that acH2A.Z contributes for gene expression deregulation 
in PCa [15].
It has been previously reported that sirtuin 1, a 
member of class III histone deacetylases (HDACs), 
negatively regulates H2A.Z levels in cardiomyocytes, 
through targeting of this histone variant to degradation 
via an ubiquitin/proteasome pathway [16]. However, the 
role of sirtuin 1 in carcinogenesis remains unclear [17, 
18]. Indeed, this HDAC is overexpressed in some cancers 
[19, 20], but downregulated in others [21], supporting its 
role either as an oncogene or a TSG. In PCa, both SIRT1 
over- and underexpression have been reported [21, 22]. 
Nevertheless, there is accumulating evidence that sirtuin 
1 mainly acts as a tumor suppressor protein [23-25], due 
to its ability to promote the activity of TSC2, a repressor 
of mTOR [26].
In this study, we aimed to uncover the putative 
regulatory role of sirtuin 1 in H2A.Z expression during 
prostate carcinogenesis and determine whether it might 
constitute a relevant therapeutic target for PCa. 
RESULTS
SIRT1 and H2AFZ are deregulated in PCa
H2AFZ and SIRT1 transcript levels were assessed 
in primary PCa, as well as in high-grade prostatic 
intraepithelial neoplasia (PIN) and morphologically 
normal prostate tissue (NPT). Relevant clinical and 
histopathological data are depicted in Table 1. No 
statistically significant differences were found for age 
between patients and controls (NPT).
Statistically significant differences were observed 
in SIRT1 and H2AFZ transcript levels among the three 
analyzed groups. Both PIN lesions and PCa showed 
downregulation of SIRT1 with concomitant overexpression 
of H2AFZ, compared to NPT (Fig. 1A). No statistically 
significant differences were disclosed for SIRT1 and 
H2AFZ expression levels between PIN and PCa samples, 
and no associations were found with clinicopathological 
variables in PCa patients.
Expression profiling of PCa cell lines LNCaP, 
DU145, and PC-3 revealed that SIRT1 and H2AFZ mRNA 
levels were within the same range as that observed in 
primary PCa tissue samples (Fig. 1B). 
Figure 1: Transcriptional status of SIRT1 and H2AFZ in clinical samples (normal prostate tissues – NPT –, prostatic 
intraepithelial neoplasia – PIN – and prostate carcinoma - PCa) and PCa cell lines (LNCaP, DU145 and PC-3). (A) 
SIRT1 downregulation and H2AFZ overexpression are early events in prostatic carcinogenesis (group analysis with Kruskal-Wallis test 
followed by a pairwise Mann-Whitney U test, **p<0.01, ***p<0.001 and ****p<0.0001); (B) SIRT1 and H2AFZ gene expression in PCa 
cell lines follow the tendency observed for clinical samples of prostatic malignancy (mean ± SD, n=3).
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Overexpression of SIRT1 decreases levels of 
H2A.Z independently of mTOR inhibition
To investigate the role of sirtuin 1 in the modulation 
of H2A.Z expression, SIRT1 overexpression was induced 
in LNCaP, DU145 and PC-3 cell lines [validation of 
successful transduction was assessed by qRT-PCR 
(Supplementary Fig. 1A) and Western blot (Fig. 2 A1 
and 2 A2)]. Following induction of SIRT1 expression, a 
significant reduction of phosphorylated ribosomal protein 
S6 (phosphoS6, an effector of mTOR pathway) was 
found, although mTOR and ribosomal protein S6 (S6) 
remained unchanged (Figs. 2 A1 and 2 A3). In addition, 
H2A.Z protein suffered an impressive reduction to 
nearly undetectable levels (Fig. 2 A1), in parallel with a 
significant reduction of its target c-Myc, in DU145 and 
PC-3 cells (Fig. 2 A4). 
In order to assess whether decreased H2A.Z levels 
were due to mTOR pathway inhibition by sirtuin 1, the 
Table 1: Clinical and histopathological features of patient populations.
Clinicopathological Features NPT PIN PCa
Patients, n
Median age, median (range)
PSA (ng/mL), median (range)
10
63 (45 - 79)
n.a.
10
63 (51 - 73)
n.a.
57
66 (51 - 74)
9.05 (2.66 - 35.50)
Pathological Stage, n (%)
pT2 n.a. n.a. 23 (40)
pT3 n.a. n.a. 34 (60)
Gleason Score, n (%)
< 7 n.a. n.a. 12 (21)
= 7 n.a. n.a. 39 (68)
> 7 n.a. n.a. 6 (11)
NPT - morphologically normal prostate tissue, PIN - prostatic intraepithelial neoplasia, PCa - prostate carcinoma, 
n.a. - not applicable.
Figure 2: Protein profile of three PCa cell lines  - LNCaP, DU145 and PC-3 – after (A1) SIRT1 overexpression, (B1) 
mTOR silencing and (C1) SIRT1 overexpression and exposure to bortezomib. After SIRT1 overexpression levels of (A2) 
sirtuin 1 increased, with concomitant decrease in (A3) pS6, (A4) c-Myc and H2A.Z. FRAP silencing induced a decrease in (B2) mTOR, 
(B3) pS6 and (B4) H2A.Z. When SIRT1 overexpressing cells were exposed to bortezomib, the increased levels of (C2) sirtuin 1 caused 
a significant decrease in H2A.Z levels (C3). However, this decrease was much less impressive than previously observed for SIRT1 
upregulation without proteasome inhibition. Results were normalized to β-actin and are presented as fold variation in comparison to control 
(mean±SD, n=3). Dunnet’s test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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selected PCa cell lines were stably silenced for FRAP, the 
gene encoding mTOR protein, and silencing validation 
was performed by qRT-PCR (Supplementary Fig. 1B) and 
Western blot (Fig. 2 B1 and 2 B2). As expected, mTOR 
pathway inhibition decreased phosphoS6 levels (Fig. 2 
B3). Furthermore, a statistically significant, but modest 
reduction in H2A.Z levels was observed following FRAP 
silencing (Fig. 2 B4). 
Pharmacological inhibition of proteasome impairs 
H2A.Z degradation caused by sirtuin 1 induced 
overexpression
Because sirtuin 1 might induce H2A.Z degradation 
through the proteasome, we evaluated whether H2A.Z 
decrease might be due to that mechanism. Hence, the 
three PCa cell lines were transiently transfected for SIRT1 
and exposed to 0.1µM bortezomib, a selective inhibitor 
of proteasomal activity (Fig. 2 C1). Although SIRT1 
overexpression (Supplementary Fig. 1C and Fig. 2 C2) 
and concomitant proteasome inhibition were associated 
with a decrease in H2A.Z levels (Fig. 2 C3), the extent 
of this decrease was considerably less impressive when 
compared to SIRT1 overexpression without proteasome 
inhibition.
Trichostatin A (TSA) leads to increased expression 
of both H2AFZ and SIRT1 through regulation of 
histone marks
To ascertain whether epigenetic modulating drugs 
were able to regulate H2AFZ and SIRT1 transcriptional 
Figure 3: Epigenetic modulating drugs positively regulate H2AFZ and SIRT1 transcription. Transcript levels of (A1) 
H2AFZ and (A2) SIRT1 in three distinct PCa cell lines after exposure to 5-aza-dC and/or TSA. The results are presented as fold variation 
in comparison to the experimental control (mean±SD, n=3). Dunnet’s test: **p<0.01, ***p<0.001, ****p<0.0001. ChIP assay results in 
LNCaP cell line regarding (B1) H2A, (B2) H2A.Z, (B3) AcH2A.Z, (B4) H3, (B5) AcH3 and (B6) H3K4me2 histones and histones marks 
across H2AFZ promoter and regarding (C1) H2A, (C2) H2A.Z, (C3) AcH2A.Z, (C4) AcH3, (C5) H3K4me2 and (C6) histones and histones 
marks along SIRT1 promoter . Results are normalized with the input of total sonicated chromatin (mean ± SD).
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status, PCa cell lines were exposed to 5-aza-2’-
depxycytidine (5-aza-dC) and/or TSA. TSA, alone or 
combined with 5-aza-dC, led to an increase in mRNA 
levels for both genes, whereas 5-aza-dC alone was not 
able to significantly alter their expression (Fig. 3 A1 and 
3 A2). Hence, the effect of 5-aza-dC alone was not further 
explored. 
Subsequently, chromatin immunoprecipitation 
(ChIP) was performed in the three selected PCa cell lines 
after exposure to TSA (Fig. 3B/3C and Supplementary 
Figs. 2, 3 and 4). For LNCaP cells, concerning H2AFZ, 
no relevant differences were found for H2A and H2A.Z 
levels within the promoter, after treatment. However, 
differences in distribution were depicted as H2A tended 
to accumulate away from the TSS (Fig. 3 B1), whereas 
H2A.Z was enriched nearby the TSS (Fig. 3 B2), 
particularly its acetylated form, and after exposure to TSA 
(Fig. 3 B3). Concurrently, after drug exposure, H3 levels 
remained stable (Fig. 3 B4) whereas the distribution of 
the activating marks acH3 and H3K4me2 was increased 
closer to the TSS (Fig. 3 B5 and 3 B6). Nevertheless, 
no variations were observed for the repressive mark 
H3K27me3 along the full extent of the H2AFZ promoter 
(Supplementary Fig. 2). Remarkably, the same results 
were observed for DU145 and PC-3, except for AcH2A.Z 
in PC-3, which was not increased after treatment with both 
drugs (Supplementary Fig. 3 and 4). 
Likewise, in LNCaP, although H2A.Z levels were 
higher than those of H2A, drug exposure did not alter 
H2A and H2A.Z levels across SIRT1 promoter (Fig. 3 
C1 and 3 C2), and both were particularly enriched nearby 
the TSS. Nonetheless, acH2A.Z levels remained very 
low and dispersed along the SIRT1 promoter (Fig. 3 C3). 
Within this same promoter, alterations in H3 levels were 
found in LNCaP (Supplementary Fig. 2). Additionally, an 
increase in histone activating marks was demonstrated in 
nucleosomes close to TSS (Fig. 3 C4 and 3 C5) whereas 
a decrease in the H3K27me3 repressive mark was found 
after epigenetic drugs exposure (Fig. 3 C6). Concurrently, 
the same observations were found in DU145 and PC-3, 
although levels of H3 remained the same for both cell 
lines (Supplementary Figs. 3 and 4). 
Epigenetic modulating drugs reduce protein levels 
of H2A.Z with concomitant increase of sirtuin 1
Because SIRT1 and H2AFZ transcript levels 
increased after exposure to TSA alone or combined with 
5-aza-dC, H2AFZ and SIRT1 protein expression was 
further assessed (Fig. 4A). Intriguingly, whereas sirtuin 1 
levels significantly increased after TSA exposure, alone 
or in combination with 5-aza-dC (Fig. 4 B1), the opposite 
trend was observed for H2AZ levels (Fig. 4 B2), as well 
as for c-Myc levels (Fig. 4 B3).
Pharmacological inhibition or activation of sirtuin 
1 directly affects regulation of H2A.Z protein 
levels
The effect of sirtuin 1 pharmacological inhibition or 
activation on H2A.Z protein levels was assessed through 
exposure of PCa cell lines to the modulators of sirtuin 1 
enzymatic activity nicotinamide (inhibitor) or resveratrol 
(activator). The same experiment was performed in 
combination with exposure to epigenetic modulating drugs 
(Figure 5).
Figure 4: Epigenetic modulating drugs have the capacity to upregulate protein levels of sirtuin 1 and decrease levels 
of H2A.Z and c-Myc. (A) Western blot analysis of sirtuin 1, H2A.Z and c-Myc of three PCa cell lines exposed to 5-aza-dC and/or TSA. 
Optical densities of visible bands for (B1) sirtuin 1, (B2) H2A.Z and (B3) c-Myc following treatment with 5-aza-dC and/or TSA. Intensity 
of the bands was normalized to the loading control β-actin and presented as folding variation in comparison to the untreated control (mean 
± SD, n=3). Dunnet’s test: *p<0.05, **p<0.01, ***p<0.001.
Oncotarget 2013; 4:1678www.impactjournals.com/oncotarget
Exposure to nicotinamide alone was associated 
with a decrease in sirtuin 1. Whereas in LNCaP cells, 
sirtuin 1 levels decreased after exposure to nicotinamide 
combined with both epigenetic drugs, in DU145 cells 
the same was observed only for nicotinamide combined 
with TSA. On the contrary, in PC-3 cells exposed to 
nicotinamide combined with TSA or 5-aza-dC plus TSA, 
an increase in sirtuin 1 levels was apparent (Fig. 5 A1 and 
5 A2). An increase in H2A.Z protein levels after exposure 
to nicotinamide alone was observed only in DU145. 
Nonetheless, an increase in H2A.Z protein levels was 
observed in all cell lines when nicotinamide was combined 
with TSA or with both epigenetic drugs (Fig. 5 A1 and 5 
A3).
In PCa cell lines exposed to resveratrol, a 
statistically significantly increase in sirtuin 1 protein 
levels was verified. This trend was more striking when 
the sirtuin 1 activator was used in combination with 
5-aza-dC and TSA (Fig. 5 B1 and 5 B2). The opposite 
effect was observed for H2A.Z levels: cell lines exposed 
to resveratrol showed a decrease in H2A.Z levels. 
Interestingly, the lowest H2A.Z levels were found in PCa 
cell lines treated with resveratrol in combination with 
5-aza-dC and TSA (Fig. 5 B1 and 5 B3).
Finally, in PC-3 cell line exposed to epigenetic 
modulating drugs, a statistically significant increase in the 
interaction between sirtuin 1 and H2A.Z was demonstrated 
using PLA, and the same result was observed following 
exposure to resveratrol alone (Figs. 6A, 6B). Additionally, 
when cells were exposed to nicotinamide, a total absence 
of signals was depicted (data not shown). 
DISCUSSION
Histone variants seem to play a major role in gene 
expression regulation. Specifically, H2A.Z and acH2A.Z 
have been shown to be deregulated in some tumors, 
causing aberrant expression of several oncogenes [9, 15, 
27, 28]. Moreover, sirtuin 1, a protein that may acts either 
as tumor suppressor or oncoprotein, has been previously 
shown to reduce H2A.Z levels in cardiomyocytes, via a 
cascade of events that ultimately leads to proteasome-
mediated histone degradation [16]. Thus, we aimed 
to characterize the role of H2A.Z deregulation in 
prostate carcinogenesis and determine how sirtuin 1 
might be involved in this process. After confirmation of 
Figure 5: Pharmacological inhibition or activation of sirtuin 1 promotes H2A.Z up- or downregulation. (A1) Western 
blot analysis of sirtuin 1 and H2A.Z of three PCa cell lines exposed to nicotinamide, alone or combined with 5-aza-dC and/or TSA. Optical 
densities of visible bands for (A2) sirtuin 1 and (A3) H2A.Z following drug exposure. (B1) Western blot analysis of sirtuin 1 and H2A.Z of 
three PCa cell lines exposed to resveratrol, alone or combined with 5-aza-dC and/or TSA. Optical densities of visible bands for (B2) sirtuin 
1 and (B3) H2A.Z following drug exposure. Intensity of bands was normalized to the loading control β-actin and presented as folding 
variation in comparison to the untreated control (mean±SD, n=3). Dunnet’s test: *p<0.05, **p<0.01, ***p<0.001.
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deregulation of SIRT1 and H2AFZ expression in primary 
PCa tissues, we found that, in PCa cell lines, induction 
of SIRT1 expression led to a dramatic decrease of H2A.Z 
levels, mostly through proteasome-mediated degradation. 
Furthermore, exposure to epigenetic modulating drugs, 
mainly TSA, was able to reverse the concomitant 
deregulation of both genes in PCa at transcript and protein 
level. In addition to histone modification, direct interaction 
of sirtuin 1 and H2A.Z at protein level is also involved in 
sirtuin 1 regulation of H2AFZ expression.
This is the first report of altered H2AFZ expression 
in localized primary PCa, as well as in its putative 
precursor lesion, PIN. Interestingly, there is a previous 
publication on a trend for increased H2A.Z expression in 
tumors from patients submitted to androgen deprivation 
therapy, suggestive of a subset of castration-resistant 
tumors over-expressing this histone variant [14]. 
Concurrently, SIRT1 decreased expression was found in 
the same dataset. This observation is, however, conflicting 
with some previous studies [22], but in line with others 
[21]. Our findings sustain the downregulation of SIRT1 in 
PCa, as well as in PIN lesions, supporting the hypothesis 
that sirtuin 1 is involved in H2AFZ regulation. It should 
be recalled that SIRT1 has been considered an oncogene 
and a tumor suppressor, depending on the cancer model 
under consideration [17, 29]. Indeed, it is known that 
sirtuin 1 is responsible for acquisition of genetic mutations 
in BCR-ABL in chronic myelogenous leukemia cells, 
conferring resistance to imatinib mesylate, which inhibits 
that tyrosine kinase [30, 31]. Additionally, SIRT1 inhibits 
p53 through deacetylation, thus increasing the possibility 
of neoplastic transformation [32], p53 regulates SIRT1 
transcription through a negative feedback loop, decreasing 
SIRT1 activity, which, in turn, increases TP53 activity 
[33]. Moreover, SIRT1 has been suggested as a tumor 
suppressor in colon cancer due to its ability to deacetylate 
and inactivate oncogenic β- catenin [23]. In the same vein, 
BRCA1 enhances sirtuin 1 activity, reducing cell growth 
and increasing apoptosis in breast cancer cells [25]. In 
PCa, sirtuin 1 has been involved in autophagy, and SIRT1 
knockdown induced PIN development, suggesting that 
SIRT1 might be a tumor suppressor gene in this cancer 
model [24]. 
We found that SIRT1 induced overexpression in PCa 
cell lines decreased H2A.Z protein levels. Since sirtuin 1 
inhibits the mTOR pathway [26], we speculated whether 
H2A.Z downregulation due to sirtuin 1 overexpression 
might be mediated by repression of mTOR pathway, 
Figure 6: PCa cells exposure to epigenetic modulating drugs and resveratrol promotes the physical and direct 
interaction between sirtuin 1 and H2A.Z. (A) PLA assay for PC-3 after exposure to 0.5μM TSA, alone or combined with 1μM 
5-aza-dC, and 40μM resveratrol (40x magnification). (B) Analysis of PLA results represented as number of signals per cell (mean±SD, 
n=50). Dunnet’s test: ****p<0.0001.
Oncotarget 2013; 4:1680www.impactjournals.com/oncotarget
which is overactive and associated with tumor progression 
in PCa [34, 35]. Our findings suggest that, although 
mTOR inhibition might contribute to sirtuin 1-related 
downregulation of H2A.Z, it is not the main responsible 
as FRAP stably silenced PCa cell lines showed only a 
slight decrease in H2A.Z levels. Thus, other mechanisms 
are involved in regulation of H2A.Z by sirtuin 1. In fact, 
when simultaneous SIRT1 overexpression and exposure 
to bortezomib were performed, levels of H2A.Z modestly 
decreased, depicting that proteasome has a major 
importance in sirtuin 1-mediated H2A.Z degradation, as 
previously described [16].
Because sirtuin 1 is a Class III HDAC, we 
hypothesized that post-translational histone modification 
might be involved in H2AFZ deregulation in PCa. 
Remarkably, exposure to epigenetic drugs (TSA alone 
or in combination with 5-aza-dC) resulted in increased 
H2AFZ levels in PCa cells and these results were 
corroborated by ChIP, which demonstrated an enrichment 
of histone activating marks, such as AcH3 and H3K4me2, 
in the TSS proximity. Nonetheless, H2A and H2A.Z 
levels remained stable after drug exposure and the 
deposition pattern of both histones suggest that H2A.Z, 
and especially acH2A.Z, replace H2A in nucleosomes next 
to the TSS, which makes the gene prone to be actively 
transcribed. Interestingly, this pattern is characteristic of 
oncogenes and actively transcribed genes [15, 36, 37], and 
supports an oncogenic function for H2AFZ. Nevertheless, 
and despite increased gene transcription, protein levels of 
H2A.Z decreased after exposure to TSA, indicating that a 
post-translational mechanism was involved in regulation 
of H2A.Z levels. Based on our results, we postulate 
that sirtuin 1 is responsible for that regulation. Indeed, 
we found that SIRT1 expression was increased, both at 
transcript and protein levels, in all PCa cell lines after 
treatment with TSA. Moreover, enrichment in activating 
marks – specifically acH3 and H3K4me2 – was observed 
near the TSS of SIRT1 gene, with a simultaneous decrease 
of the repressive mark H3K27me3. Hence, our results 
strongly suggest that epigenetic modulating drugs are 
able to increase SIRT1 expression through histone post 
translational modifications. Remarkably, in contrast 
to H2AFZ, although levels of H2A.Z were increased 
nearby the SIRT1 TSS, the canonical histone was not 
depleted, depicting a common feature of poised or poorly 
transcribed genes in cancer cells [15]. Importantly, 
we demonstrated that H2A.Z is not acetylated within 
nucleosomes neighboring SIRT1 TSS, either before 
or after TSA exposure, which is in accordance with a 
previous study in PCa, regarding TSG [15]. Interestingly, 
it has been reported that sirtuin 1 not only regulates H2A.Z 
levels, but also that H2A.Z itself might influence SIRT1 
expression, suggesting a reciprocal regulation mechanism 
between both proteins [7, 16]. Thus, we are tempted to 
speculate that H2A.Z overexpression negatively regulates 
SIRT1, resulting in the lower sirtuin 1 levels observed in 
PCa cell lines and primary tissues.
To ascertain the impact of sirtuin 1 activity on 
H2A.Z levels, we tested an inhibitor (nicotinamide) and 
an activator (resveratrol) of sirtuin 1 alone or combined 
with epigenetic modulating drugs. Remarkably, the effect 
on H2A.Z protein levels was independent of exposure to 
the epigenetic modifying drugs, demonstrating that sirtuin 
1 also regulates H2A.Z levels through its direct enzymatic 
activity. Intriguingly, we found that nicotinamide induced 
a decrease of sirtuin 1 levels and similar results have 
already been reported in leukemic cells [38]. Contrarily, 
resveratrol alone induced an increase in sirtuin 1 protein 
levels, which is line with previous reports showing that 
it promotes SIRT1 expression [39]. Hence, the combined 
Figure 7: Interplay among sirtuin 1, H2A.Z, mTOR and c-Myc in prostate cancer cells. (A) Under normal conditions, PCa 
cells display downregulation of SIRT1, thus, sirtuin 1 is unable to promote H2A.Z negative regulation directly, through its degradation, 
and indirectly, through mTOR pathway repression, leading to upregulation of c-Myc and other oncogenes. (B) When exposed to TSA, 
alone or combined with 5-aza-dC, or resveratrol, levels of sirtuin 1 are restored, leading to decreased levels of H2A.Z, partially due to 
mTOR pathway inhibition, but mostly via direct interaction between sirtuin 1 and the histone variant. Similarly, c-Myc levels decrease after 
treatment with those drugs. 
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effect of activation and induced expression of sirtuin 
1 by resveratrol substantiates the observed decrease in 
H2A.Z protein levels. Importantly, exposure to epigenetic 
modifying drugs augmented this effect, mainly through 
increased SIRT1 expression, as expected.
Importantly, we found that the mechanism by 
which sirtuin 1 promotes H2A.Z downregulation involves 
proteasomal-mediated degradation. This mechanism has 
been previously demonstrated in cardiomyocytes, in 
which increased deacetylation of Lys-15 triggers H2A.Z 
ubiquitylation on Lys-115 and Lys-121 and, ultimately, its 
degradation by the proteasomal pathway [16]. To further 
support this hypothesis in PCa cells, we showed, through 
PLA, that exposure to epigenetic modulating drugs 
dramatically increased the interaction between sirtuin 1 
and H2A.Z, promoting their physical contact which is 
critical for degradation.
Interestingly, H2A.Z, a histone variant consistently 
associated with the malignant phenotype, might constitute 
an interesting therapeutic target [27]. Concerning the 
mechanism that regulates H2A.Z incorporation into 
nucleosomes, the ATP dependent nucleosome remodeler 
SNF-2-related CREB-binding protein activator protein 
(SRCAP) inserts H2A.Z into nucleosomes and deposits 
it near gene promoters [40, 41]. Remarkably, SRCAP has 
been already reported to be overexpressed in PCa [42]. 
Additionally, p400/Tip60, another complex responsible 
for H2A.Z insertion into chromatin, is also overactive 
in PCa [43]. Although a therapy based on SRCAP or 
p400/Tip60 repression would seem attractive, specific 
targeting of those complexes might entail high toxicity 
to non-neoplastic cells. Furthermore, it has been reported 
that H2A.Z and c-Myc, a transcription factor highly 
expressed in PCa [44], positively regulate each other, with 
high levels of the histone variant colocalized in C-MYC 
promoter during active transcription [9, 12]. Hence, 
targeting of c-Myc might not only regulate this protein, 
but it would also allow for indirect regulation of H2A.Z. 
Nevertheless, anti-c-Myc based therapy is changeling 
and displays high toxicity, since C-MYC expression is 
ubiquitous in all proliferating, including non-malignant, 
cells [45].
Interestingly, a close correlation between sirtuin 1 
and c-Myc has been already reported, and a synergistic 
effect has been demonstrate for these two proteins [46-
49], suggesting an oncogenic role for sirtuin 1. However, 
it is known that the oncogenic role of sirtuin 1 is tumor- 
and context-specific, and the opposite relation between the 
histone deacetylase and c-Myc has already been described, 
indicating that sirtuin 1 promotes c-Myc instability 
[50]. Although in a different mechanistic context, we 
also observed a negative correlation between sirtuin 1 
and c-Myc oncoprotein. Hence, we demonstrated that 
epigenetic modulation of H2A.Z, mediated by sirtuin 1 
upregulation, decreased c-Myc expression, which might 
provide a more effective and less toxic alternative.
In conclusion, we showed that sirtuin 1 and 
H2A.Z deregulation in PCa are reciprocally related. 
Epigenetic mechanisms, mostly histone post-translational 
modifications, are likely involved and impair sirtuin 
1-mediated downregulation of H2A.Z via proteasome-
mediated degradation. Epigenetic modifying drugs in 
conjunction with enzymatic modulators are able to restore 
the normal functions of sirtuin 1 and might constitute 
relevant tools for targeted therapy of PCa patients (Fig. 7).
MATERIALS AND METHODS
Patients and Samples
Fifty-seven PCa samples were prospectively 
collected from patients diagnosed and treated with radical 
prostatectomy at the Portuguese Oncology Institute 
– Porto, Portugal. From 10 of those patients, samples 
of PIN were also collected. Ten NPT, used as controls, 
were obtained from the peripheral zone of prostates 
that did not harbor PCa of patients submitted to radical 
cystoprostatectomy for bladder cancer. After surgery, all 
tissues specimens were promptly frozen at -80ºC and 
subsequently cut in a cryostat for nucleic acid extraction.
From each specimen, fragments were routinely 
collected, formalin-fixed and paraffin-embedded for 
histopathological examination. An expert pathologist 
evaluated Gleason score and pathological staging. 
Relevant clinical data was collected from the clinical 
charts. This study was approved by the institutional review 
board (Comissão de Ética para a Saúde) of Portuguese 
Oncology Institute - Porto, Portugal.
Prostate cancer cells
LNCaP cells were grown in RPMI 1640, DU145 
cells were maintained in MEM and PC-3 cells were 
grown in 50% RPMI-50% F-12 medium (GIBCO), as 
recommended. All culture media were supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin 
(GIBCO). Cells were maintained in an incubator at 37ºC 
with 5% CO2. All PCa cell lines were karyotyped by 
G-banding (for validation purposes) and routinely tested 
for Mycoplasma spp. contamination (PCR Mycoplasma 
Detection Set, Clontech Laboratories).
Transient transfection
PCa cells were transiently transfected with 
transfection-ready DNA containing SIRT1 transcript 
variant 1 (Origene Technologies), following 
manufacturer’s instructions. After transfection, SIRT1-
overexpressing cells were also exposed to 0.1µM 
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bortezomib (Cell Signaling) and subsequently harvested 
for RNA and protein extraction.
Short hairpin RNA (shRNA) and lentiviral 
transduction
Cells were transfected with mTOR or negative 
control shRNA using shRNA Lentiviral Particles (sc-
35409-V and sc-108080, respectively, Santa Cruz 
Biotechnology), according to manufacturer’s indications. 
Clones successfully silenced were selected using the 
recommended complete medium supplemented with 2-5 
µg/mL puromycin, as recommended by manufacturer. 
Cells were then collected for RNA and protein extraction.
Cell culture and treatment with epigenetic 
modulating drugs, nicotinamide and resveratrol
PCa cells treated with 1µM 5-aza-dC (Sigma) for 
72h and 0.5µM TSA (Sigma), added the last 24h. Cells 
were also exposed to 20mM nicotinamide (Sigma) or 
40µM resveratrol (Sigma) for 72h, both alone or in 
combination with TSA or 5-aza-dC and TSA, according to 
the previous regimen. For control purposes, the same cell 
lines were cultured without treatment for 72 hours (mock 
cells). For each condition, three biological replicates were 
performed. Both medium and drugs were replaced every 
24h.
RNA isolation and quantitative reverse-
transcription PCR (qRT-PCR)
Total RNA from tissue samples and cell lines was 
isolated using Trizol® Reagent (Invitrogen) and all 
genomic DNA present in the samples was eliminated 
using TURBO DNA-free (Ambion, Applied Biosystems), 
following manufacturer’s instructions. For each sample, 
first strand synthesis was performed using the High-
Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Expression of target genes was quantified 
using TaqMan expression assays [H2AFZ (Hs01888362_
g1), SIRT1 (Hs01009005_m1), FRAP (Hs00234508_
m1)], acquired as pre-developed assays from Applied 
Biosystems and normalized to the expression of the 
endogenous control GUSB (Hs99999908_m1). The 
standard curve method was used to determine RNA levels. 
All samples were analysed in triplicate, and the mean 
value was used for data analysis. 
Whole-cell extracts and immunoblot
Whole-cell protein extraction was performed using 
complete RIPA Buffer (Santa Cruz Biotechnology Inc.). 
Briefly, 20μg of total protein were separated by SDS-
PAGE, transferred to nitrocellulose membranes and 
probed with antibodies against H2A.Z (Cell Signaling), 
sirtuin 1 (Abcam), mTOR (Cell Signaling), S6 (Cell 
Signaling), pS6 (Cell Signaling), c-Myc (Abcam) or the 
endogenous control β-actin (Sigma). Finally, blots were 
developed using Immun-Star WesternC Kit, according to 
manufacturer’s indications (BioRad). All the experiments 
were performed in triplicate. Relative optical density 
determination was performed using QuantityOne Software 
version 4.6.6. (Biorad) and normalized for the loading 
control, β-actin.
Chromatin immunoprecipitation (ChIP) Assay
EZ-Magna ChIP G-Chromatin Immunoprecipitation 
Kit and the Magna Grip Rack (Millipore) were used to 
perform ChIP assay according to the manufacturer’s 
instructions. For each chromatin immunoprecipitation 
assay, anti-H2A (Abcam), anti-H2A.Z (Abcam), anti-
AcH2A.Z (Abcam), anti-H3 (Abcam), anti-AcH3 
(Millipore), anti-H3K4me2 (Abcam), anti-Histone 
H3K27me3 (Millipore) and the negative control provided 
with the kit (normal mouse IgG), were used. 
DNA quantification was performed in a 7500 Real-
Time PCR System (Applied Biosystems), using Power 
SYBR Green PCR Master Mix (Applied Biosystems). 
Three gene-specific pairs of primers for each gene 
promoter were used, in which primers A were located 
closer to TSS and C those that were more distant upstream 
TSS (Supp. Table 1). The relative amount of promoter 
DNA was normalized using Input Percent Method.
Proximity ligation assay (PLA)
PC-3 cells, cultured in 1cm2 coverslips, were 
exposed to 0.5µM TSA (Sigma), alone or combined 
with 1µM 5-aza-dC (Sigma), and to 40µM resveratrol 
(Sigma), as previously mentioned. Additionally, Mock 
cells were used as controls. At the end of treatment, cells 
were fixed in 4% formaldehyde (Sigma) for 10 minutes 
and permeabilized in 0.5% Triton X-100 (Sigma), for 5 
minutes, at room temperature and gently stirred.
PLA assay was performed using the commercial 
kit Duolink In Situ (OLINK Bioscience), according to 
manufacturer’s instructions. The antibodies used were 
anti-sirtuin 1 (Abcam) and anti-H2A.Z (Cell Signaling). 
After the procedure, slides were evaluated under a 
fluorescence microscope (Olympus IX51, Olympus). PLA 
signals were counted in fifty randomly selected cells for 
each treatment.
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Statistical analysis
In cell lines, differences in transcript and protein 
levels among the treatments performed were determined 
using One-Way Analysis of Variance (one-Way ANOVA), 
followed by a multiple comparison Dunnet’s (post-hoc) 
test, or Student’s t-test, as appropriate, comparing all 
groups against the Mock. 
Differences in quantitative expression levels of 
SIRT1 and H2AFZ among NPT, PIN and PCA were 
assessed by the nonparametric Kruskall-Wallis test, 
followed by pairwise comparisons through Mann-Whitney 
U-test with Bonferroni’s correction, when appropriate. 
The relationship between expression levels and standard 
clinicopathological variables (Gleason score, pathological 
stage) were assessed using the Kruskall- Wallis or the 
Mann-Whitney tests, as appropriate. 
All tests were two-sided and statistical significance 
was set at p<0.05. Statistical analysis was performed using 
GraphPad Prism version 5.0 for Windows (GraphPad 
Software).
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